Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen

Jan Kempski; Samuel Huber

doi:10.1007/s00108-022-01396-8

Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen

Standard

Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen. / Kempski, Jan ; Huber, Samuel.

In: INNERE MED, Vol. 63, No. 10, 10.2022, p. 1022-1027.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Kempski, J & Huber, S 2022, 'Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen', INNERE MED, vol. 63, no. 10, pp. 1022-1027. https://doi.org/10.1007/s00108-022-01396-8

APA

Kempski, J., & Huber, S. (2022). Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen. INNERE MED, 63(10), 1022-1027. https://doi.org/10.1007/s00108-022-01396-8

Vancouver

Kempski J , Huber S. Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen. INNERE MED. 2022 Oct;63(10):1022-1027. https://doi.org/10.1007/s00108-022-01396-8

Bibtex

@article{bb4b79a96d144b82a4e24d15f49bd650,

title = "Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entz{\"u}ndlicher Darmerkrankungen",

abstract = "Inflammatory bowel diseases (IBD) are systemic diseases that mainly manifest in the gastrointestinal tract. Due to chronically impaired intestinal homeostasis, they often require permanent and in some cases systemic therapy. The exact causes of IBD are largely unknown. It is postulated that these complex diseases arise in genetically susceptible individuals through a misdirected immune response, promoted by barrier defects, environmental toxins, and the gut microbiome. In this regard, the importance of the microbiome and its pathogenic changes (dysbiosis) in the pathogenesis of IBD is increasingly coming into focus. This review article presents the current state of research on the role of the microbiome in the development of IBD. Therapeutic approaches aimed at correcting intestinal dysbiosis are also discussed.",

keywords = "Dysbiosis/therapy, Fecal Microbiota Transplantation, Gastrointestinal Microbiome, Humans, Inflammatory Bowel Diseases/etiology, Intestines",

author = "Jan Kempski and Samuel Huber",

note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2022",

month = oct,

doi = "10.1007/s00108-022-01396-8",

language = "Deutsch",

volume = "63",

pages = "1022--1027",

journal = "INNERE MED",

issn = "2731-7080",

publisher = "Springer Medizin",

number = "10",

}

RIS

TY - JOUR

T1 - Das Darmmikrobiom in der Pathogenese und Therapie chronisch-entzündlicher Darmerkrankungen

AU - Kempski, Jan

AU - Huber, Samuel

PY - 2022/10

Y1 - 2022/10

N2 - Inflammatory bowel diseases (IBD) are systemic diseases that mainly manifest in the gastrointestinal tract. Due to chronically impaired intestinal homeostasis, they often require permanent and in some cases systemic therapy. The exact causes of IBD are largely unknown. It is postulated that these complex diseases arise in genetically susceptible individuals through a misdirected immune response, promoted by barrier defects, environmental toxins, and the gut microbiome. In this regard, the importance of the microbiome and its pathogenic changes (dysbiosis) in the pathogenesis of IBD is increasingly coming into focus. This review article presents the current state of research on the role of the microbiome in the development of IBD. Therapeutic approaches aimed at correcting intestinal dysbiosis are also discussed.

AB - Inflammatory bowel diseases (IBD) are systemic diseases that mainly manifest in the gastrointestinal tract. Due to chronically impaired intestinal homeostasis, they often require permanent and in some cases systemic therapy. The exact causes of IBD are largely unknown. It is postulated that these complex diseases arise in genetically susceptible individuals through a misdirected immune response, promoted by barrier defects, environmental toxins, and the gut microbiome. In this regard, the importance of the microbiome and its pathogenic changes (dysbiosis) in the pathogenesis of IBD is increasingly coming into focus. This review article presents the current state of research on the role of the microbiome in the development of IBD. Therapeutic approaches aimed at correcting intestinal dysbiosis are also discussed.

KW - Dysbiosis/therapy

KW - Fecal Microbiota Transplantation

KW - Gastrointestinal Microbiome

KW - Humans

KW - Inflammatory Bowel Diseases/etiology

KW - Intestines

U2 - 10.1007/s00108-022-01396-8

DO - 10.1007/s00108-022-01396-8

M3 - SCORING: Review

C2 - 36044059

VL - 63

SP - 1022

EP - 1027

JO - INNERE MED

JF - INNERE MED

SN - 2731-7080

IS - 10

ER -